ReShape Lifesciences Accounts Payable

ReShape Lifesciences (RSLS) currently reports a accounts payable of $1.1M as of June 2026. That compares with $1.3M in the prior-year period — down 20.9% year over year. Use the charts on this page to explore ReShape Lifesciences's accounts payable history and peer comparisons.

ReShape Lifesciences's accounts payable decreased from $1.3M to $1.1M — a 20.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ReShape Lifesciences reported $1.1M in accounts payable as of June 2026. That compares with $1.3M in the prior-year period — down 20.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.1M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ReShape Lifesciences, and consider following RSLS for alerts when major investors trade the stock.

ReShape Lifesciences is classified in the Healthcare sector. On accounts payable, it currently shows $1.1M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RSLS with unrelated industries.